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Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USAEarly preclinical studies in rodents and other species did not
reveal that vector or transgene immunity would present a sig-
nificant hurdle for sustained gene expression. While there
was early evidence of mild immune responses to adeno-associ-
ated virus (AAV) in preclinical studies, it was generally believed
that these responses were too weak and transient to negatively
impact sustained transduction. However, translation of the
cumulative success in treating hemophilia B in rodents and
dogs with an AAV2-F9 vector to human studies was not as suc-
cessful. Despite significant progress in recent clinical trials for
hemophilia, new immunotoxicities to AAV and transgene are
emerging in humans that require better animal models to
assess and overcome these responses. The animal models
designed to address these immune complications have pro-
vided critical information to assess how vector dose, vector
capsid processing, vector genome, difference in serotypes,
and variations in vector delivery route can impact immunity
and to develop approaches for overcoming pre-existing immu-
nity. Additionally, a comprehensive dissection of innate,
adaptive, and regulatory responses to AAV vectors in preclini-
cal studies has provided a framework that can be utilized for
development of immunomodulatory therapies to overcome
or bypass immune responses and for developing strategic
approaches toward engineering stealth AAV vectors that can
circumvent immunity.
Adeno-Associated Virus
Adeno-associated virus (AAV) is a single-stranded DNA dependovi-
rus and member of the parvovirus family. The wild-type genome of
AAV is 4.7 kb coding for replication (rep) and structural (cap)
proteins. AAV infection is not associated with any disease in humans
and other mammals, which are natural hosts for AAV, and the wild-
type virus is weakly immunogenic. However, AAV replication is
dependent on immunogenic helper viruses that promote inflamma-
tion, resulting in humoral and cell-mediated immune responses
directed against the AAV capsid proteins. Thus, from natural infec-
tion, humans may have pre-exiting immunity with antibodies and
immunological memory against the AAV capsid.https://doi.org/10.1016/j.omtm.2019.12.008.
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AAV vectors are generated by replacing the rep and cap genes with a
transgene expression cassette, while retaining the flanking cis viral198 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2
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serotypes, natural or engineered, can be used to cross-package AAV
genomic DNA with AAV2 ITRs to direct vector tropism to a target
tissue or organ.1 The AAV vector genome can be packaged as
single-stranded (ssAAV) DNA, similar to wild-type AAV or self-
complementary (scAAV) with double-stranded DNA.1 The viral
capsid is made up from three proteins VP1, VP2, and VP3, in which
VP2 and VP3 are shortened versions of VP1. Thus, the capsid
proteins and transgene product constitute the only immunological
antigens. However, since the viral capsids are derived from wild-
type AAVs, AAV vectors can be recognized by pre-existing adaptive
immune responses.
Clinical Experience with AAV Vectors
Presently, there are two FDA approved AAV biologicals for the treat-
ment of inherited blindness (Leber’s congenital amaurosis) and spinal
muscular atrophy (SMA).2,3 Additionally, there are a substantial
number of AAV gene therapy clinical trials evaluating therapeutic
efficacy for a number of diseases. However, despite the accelerated
use of AAV in clinical studies, there have been repeated reports of tox-
icities that have compromised transgene product expression.4–6 In
some studies, immune responses against either the AAV capsid or
transgene product have been identified as contributing to the reduc-
tion or complete loss of expression. Despite the fact that AAV vectors
have a small immunological footprint, infection of humans with wild-
type AAV and cross-reactive responses to different AAV serotypes
poses a risk for sustained transgene expression. Further, the use of
ever-higher vector doses in clinical trials may reveal new toxicities
and require reevaluation of current immune suppression protocols.
Innate Immune Responses to AAV Vector
Innate Immunity
Host innate immunity recognizes and rapidly responds to microor-
ganisms and pathogens through recognition of pathogen-associated
molecular patterns (PAMPs), common shared structural features
found on microorganisms and pathogens.7–9 These PAMPs are
recognized by pattern recognition receptors (PRRs), largely expressed020 ª 2019 The Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
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cells for linking innate and adaptive immune responses.7–9 Toll-like
receptors (TLRs) are the most studied PRRs and are strategically
localized on the cell surface or intracellularly in the endosome for
early detection of invading pathogens. The endosomal TLRs (TLR3,
TLR7, TLR8, and TLR9) recognize viral nucleic acids (ssRNA,
dsRNA, ssDNA, and dsDNA), respectively, typically following recep-
tor-mediated endocytosis of virus. For example, the unmethylated
CpG DNA viral genome of a DNA virus, such as an AAV and
AAV vectors, is sensed by TLR9 and leads to the activation of an
anti-viral immune response mediated by the release of type I inter-
ferons (IFNs) and induction of a T helper 1 (Th1) adaptive immune
response. The surface TLRs (TLR2, TLR4, TLR5, and TLR6) typically
recognize extracellular microorganisms and trigger host innate im-
munity through acute phase, neutrophil, and other pro-inflammatory
responses and largely shape a Th2 adaptive immune response. Many
pathogens are sensed by both surface and endosomal TLRs. Proposed
innate ligands of AAV vectors include the AAV capsid,10 CpG
containing AAV genome,11 and dsRNA.12
Innate Recognition of AAV Vectors
A comparative study of immune responses to AAV and adenovirus
(Ad) vectors provided early awareness that AAV vectors could trigger
innate immune responses in mice.13 However, pro-inflammatory
cytokine responses to AAV vectors was transient with a pronounced
response 1 h post intravenous (i.v.) injection but returned to baseline
6 h post injection. Liver infiltration of neutrophils and macrophages
showed a similar time course, and liver necrosis was only evident in
Ad vector-treated mice.14 The differential response between AAV
and Ad may be attributed, in part, to differences in their genomes
as Ad is a dsDNA virus, which is a more effective TLR9 agonist
than the ssDNA AAV vector genome.15 AAV infection of plasmacy-
toid dendritic cells (pDCs) and conventional dendritic cells (cDCs)
isolated from mice deficient in TLR9 and myeloid differentiation
primary response protein 88 (MyD88) and not TLR2 or Trif proteins
had significantly reduced secretion of type I IFNs specifically in
pDCs.11 This activation was independent of both capsid serotype
and transgene. DNase treatment of vector confirmed that the AAV
genome was the primary TLR9 ligand. Further, adaptive immune
responses to intramuscular (IM) delivery of an AAV vector and the
transgene product were shown to be dependent on innate sensing
by TLR9, MyD88, and type I interferon receptor (IFNR).11 Innate im-
mune responses in the liver were investigated following i.v. ssAAV
and scAAV vector administration in mice.16 Activation of pro-in-
flammatory genes was shown to be TLR9 dependent and was
observed only with scAAV vectors, independent of capsid serotype.16
The innate response was rapid, appearing within 2 h after gene trans-
fer, and transient, resolving 9 h post vector.16 Of note, of the different
PRRs measured, mRNA levels of TLR9 was significantly upregulated
only with scAAV vectors along with a mild elevation in TLR2. Scoring
of liver inflammation revealed that increased levels of neutrophils,
macrophages, and natural killer (NK)-cells were only observed in
mice infused with a scAAV vector and could be prevented by co-
administration of a TLR9 antagonist.16MoleculDo the dsRNA-MediatedResponses Play a Role Innate Immunity
to AAV Vectors?
The generation of dsRNA following AAV gene delivery and activa-
tion of cytoplasmic RIG-1/MDA5 innate sensors was proposed as
an alternative explanation for immunotoxicities observed in clinical
trials.12 This study hypothesized that bidirectional transcription facil-
itated by the inherent promoter activity of the AAV ITRs could
generate negative-strand RNAs and trigger a dsRNA-mediated innate
immune response. Using a scAAV-hFIX-opt vector, gene expression
of MDA5, RIG1, and interferon-b (IFN-b) and transduction was
assessed at 4 and 8 weeks in mice with humanized livers—mouse
livers partially reconstituted with human hepatocytes. A mild
2-fold increase in gene expression of MDA5 and RIG1 and a less
than 2-fold drop in transduction was reported.12 Of note, a significant
increase in IFN-b expression was reported at 4 weeks in two animals
and at 8 weeks in one animal. The significance of these results is some-
what limited by the small number of immune-deficient mice studied
and may not reflect responses in immune competent mice. It should
be noted that the proposed role of ITR promoter activity in the
generation of dsRNA is somewhat controversial and that it can result
in inconsistent innate activation. A recent study found that co-admin-
istration of a TLR7 agonist (to mimic dsRNA sensing) along with IM
delivery of a ssAAV vector failed to reduce transgene product levels in
mice, raising doubts about whether dsRNA sensing is relevant in
priming AAV vector and transgene product adaptive immune
responses.17 Thus, the role of dsRNA in the overall innate sensing
of AAV vectors remains unclear and requires further study.
Innate Recognition Shapes Adaptive Responses to Capsid and
Transgene Product
Co-administration of TLR2, TLR4, TLR7, or TLR9 ligands with IM
delivery of an AAV vector was studied to determine the impact on
adaptive immune responses to both AAV vector and transgene
product. Mice receiving a TLR9 agonist along with IM delivery of
ssAAV-F9 vector were the only group to have a transient increase
in factor IX protein (FIX) antibodies.17,18 Overall, these data show
that TLR9 is critical in forming adaptive responses following AAV
vector administration. Complimentary studies in mice deficient in
intrinsic components of innate recognition and activation (TLR2/,
TLR4/, TLR7/, TLR8/, TLR9/, and MyD88/) have
revealed critical sensors and immune cells needed for Th1 antibody
responses to AAV vectors.19,20 In terms of capsid antibody responses,
the only difference noted was a deviation from a Th1 to Th2 capsid
antibody response in MyD88/ mice independent of delivery route
(IM or i.v.). Whereas both TLR9 and MyD88 were shown to affect
transgene product-specific T cell adaptive responses.19
Summary of Preclinical Studies on Innate Immune Responses to
AAV Vectors
TLR-specific and downstream innate signaling knockout mice have
been essential in defining critical PRRs that sense AAV vectors. In
mice, a scAAV vector is required to induce a measurable innate im-
mune response to AAV vector delivery to the mouse liver,16 despite
clear evidence of adaptive immune responses in ssAAV-treatedar Therapy: Methods & Clinical Development Vol. 17 June 2020 199
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have demonstrated inflammatory, humoral, and adaptive responses,
there is often no change in the levels of the transgene product. For
example, in C57BL/6 mice, co-delivery of a TLR9 agonist with IM
AAV vector delivery was needed to impact transgene-specific adap-
tive immune responses,17,18 whereas in other strains, IM AAV vector
delivery alone is sufficient for inducing adaptive immune responses.
Despite these limitations, murine studies on innate immunity to
AAV vectors have revealed an important role for TLR9-MyD88
recognition and signaling in activating inflammatory responses and
modulating adaptive responses to both AAV vectors and their trans-
gene products. However, there have been limited reported studies in
large animal models on innate sensing of AAV vectors. Recent studies
in non-human primates (NHPs) have reported innate immune
responses following administration of AAV vectors into the immune
privileged eye.21,22
Adaptive Immune Responses to AAV Vector
Linking Innate and Adaptive Immunity
Innate immunity is a critical component to an effective adaptive im-
mune response, which includes humoral immunity (B cells) and cell-
mediated immunity (CD8+ T cells).9 Unlike innate immune cells,
adaptive immune cells possess antigen-specific receptors generated
through recombination and somatic hypermutation and are capable
of recognizing a vast repertoire of antigens.23 Activated APCs upregu-
late cell surface expression of co-stimulatory molecules, major histo-
compatibility class II molecules (MHC II), and release inflammatory
cytokines, which lead to activation of both B and T cells.23 CD4+ T
helper cells play a central role in enhancing adaptive immunity by
providing additional co-stimulatory signaling and cytokines to aid
in the maturation and class switching of B cells, activation of CD8+
T cells, and immunological memory.23 Thus, strategies preventing
the activation of APCs or CD4+ T helper cells have become a major
focus for preventing AAV vector immune responses.
Pre-existing Immunity to AAV
AAV and associated parvoviruses naturally infect mammals and thus,
investigators should be aware of the impact of pre-existing adaptive
immune responses, capsid neutralizing antibodies (NAbs), and mem-
ory capsid CD8+ T cells when designing their studies.24–26 Further,
patients with pre-existing NAbs are presently excluded from clinical
trials and this can range from 20%–70% of eligible patients depending
on region and capsid serotype.27 However, capsid T cell responses
were not considered to be prohibitive until immunotoxicities were
identified in clinical trials,4,6 as animal studies did not predict this
outcome.6 NHPs with AAV8 pre-existing NAbs effectively block
AAV8 liver gene transfer28 and often these NAbs can cross-react
with other capsid serotypes.29 Thus, it is important to consider the
impact of pre-existing AAV immunity in NHPs when designing
and reporting studies, particularly for those investigators outside of
the gene therapy field.30 AAV9 NAbs can inhibit intrathalamus
delivery of an AAV9 vector in mice suggesting that even direct tissue
injection into the immune privileged CNS may not avoid pre-existing
NAbs.26 Studies in NHPs revealed that memory capsid CD8+ T cells,200 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2derived from wild-type AAV8 infection, were unable to eliminate
AAV8 transduced hepatocytes28 in contrast to observations in human
clinical trials.4 Immunological profiling showed that both CD4+ and
CD8+ capsid reactive T cells in NHPs displayed functional and
phenotypic differences as compared to humans.31
AAV Capsid NAbs and Screening
Despite transiently activating innate immunity,13 natural infection
with AAV and injection of AAV vectors results in NAb formation.
Since both neutralizing and non-neutralizing capsid antibodies are
formed, detection of antibodies by ELISA alone is uninformative32
and functional NAb assays have become a standard for screening
patients. Interestingly, non-neutralizing antibodies may positively
impact gene transfer as one study demonstrated that antibody bind-
ing initially increased liver transduction of an AAV8 vector and
enhanced vector genome copy number in the liver compared to con-
trols.32 AAVNAb assays are typically conducted using serial dilutions
of the test plasma with the appropriate AAV test vectors in vitro on a
target cell line or in vivo using passive immunization of the test
plasma into mice.26,33–36 Recently an alternative in vitro method
was published that measures AAV cell binding inhibition by
qPCR.37 However, these assays have their inherent benefits and lim-
itations.26,38 At present, there is no standardized protocol used to
conduct in vitroNAb assays, making it challenging to compare results
among different investigators. Alternatively, several studies present
some limitations to in vivo Nab assays such as reduced sensitivity
to in vitro testing,33 not mimicking in vivo generated NAb,26 and
not being effective at high throughput screening.38
Mechanisms and Prevention of Capsid NAbs
AAV vector-derived capsid NAbs are dependent on route of vector
administration39 and viral particle uptake by APCs and presentation
to CD4+ T cells.40,41 In mice, complement interaction with AAV vector
particles facilitates macrophage uptake and activation.42 In vitro studies
with human PMBCs from wild-type AAV-infected donors showed a
role for interleukin-1b (IL-1b) in B cell maturation and capsid NAb
production, which was confirmed in mice using a neutralizing IL-1b
antibody.43 Several studies in knockout mice have shown that TLR9
may or may not be dispensable for capsid Nab formation, whereas
loss of downstream signaling mediator MyD88, particularly in B cells,
significantly reduced NAb titers and shifted antibodies from a Th1
(IgG2c) to a Th2 (IgG1) immune response.11,19 Prophylactic immune
modulation has been shown to prevent capsidNAb through a variety of
B and T cell targeted therapies including: downregulation of CD4 on
T cells with the antioxidant MnTBAP,44 a non-depleting ND-CD4
antibody,40 B cell depletion with anti-CD20, or rapamycin nanopar-
ticles.45 However, the duration and choice of immune suppression
regimen can impact the effectiveness of preventing capsid NAbs. In
NHPs, tacrolimus and mycophenolate mofetil (MMF) failed to
completely prevent capsid NAbs, with one animal showing an elevated
NAb titer following cessation of immune suppression.28 A combina-
tion of MMF, anti-thymocyte immunoglobulin, methylprednisolone,
tacrolimus, and rituximab over a course of 12 weeks prior to and
following i.v. delivery of an AAV5 vector showed control of capsid020
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tion of immune suppression.46
Circumvention of Capsid NAbs
Early studies in NHP with pre-existing AAV8 NAbs and mice with an
in vivo passive immunization assay demonstrated that low AAV NAb
titers can prevent liver transduction following i.v. AAV8 vector deliv-
ery.36 Additionally, studies in mice revealed slow circulatory clearance
rates of AAV2 or AAV8 vectors,47 potentially increasing the risk for
neutralization. Temporary removal of anti-AAV capsid antibodies by
saline flush of the portal vein,48 plasmapheresis,49 and plasmapheresis
with immunoadsorption50 has proven effective for improving trans-
duction. In vivo administration of a proteasome inhibitor (PI), bortezo-
mib, eliminated hypersensitive antibody-producing plasma cells and
significantly reduced AAV Nab titers for vector re-administration.51
Alternatively, AAV8-cF8 treated hemophilia A dogs demonstrated a
significant reduction in AAV8 NAb titers 8 years after initial dosing
of vector with bortezomib, allowing for vector re-administration.52 Im-
mune suppression with rituximab (anti-CD20) and cyclosporine A
(CsA) was tested in NHPs following i.v. delivery of an AAV8 vector;
however, this failed to significantly reduce AAV8 Nab titers, but
investigators reported a reduction in cross-reactive AAV6 NAbs that
allowed for vector re-administration.53
Vector modifications including the use of alternative serotypes,54,55
empty decoy capsids,56 and exosome enveloped AAV vector parti-
cles57 have also shown success in animal studies avoiding pre-existing
capsid NAbs. However, flexibility may be limited for switching to an
alternative serotype because of cross-reactive neutralizing capsid
antibodies. While studies in mice and NHPs56 and humans58 were
conducted with formulated vector preps containing empty decoy cap-
sids, such excessive capsid loads may lead to immunotoxicities.5
Alternatively, direct tissue injection, such as IM delivery, may bypass
pre-existing capsid NAb, but this may increase the risk of transgene
immunity59 and may not always work.26
Animal Models to Address AAV5 Vectors Resistance to NAbs
Since AAV5 is the most structurally divergent of the naturally isolated
AAV capsids, it was hypothesized to have a reduced risk of neutrali-
zation, both directly and indirectly by avoiding cross-reactive NAbs.
Therefore, several groups have developed AAV5-based vectors for
clinical trials including hemophilia A and B and acute intermittent
porphyria.60–62 However, there has been some controversial results
published regarding NAbs to AAV5. One group evaluating an
AAV5 vector for hemophilia B therapy presented data that AAV5
vectors can successfully transduce liver in the presence of NAbs using
plasma from clinical trial participants and NHP studies.63 More
recently, another group evaluating an AAV5 vector for hemophilia
A gene therapy reported that 4 of 5 NHPs positive for capsid antibody
(TAb+) and transduction inhibition (TI+) had a considerable reduc-
tion in circulating human FVIII levels compared to Tab and
TAb TI+ animals.64 The data demonstrate that lack of standardiza-
tion and reliance on in vitro assays makes it challenging to compare
results and predict in vivo outcomes.MoleculCytotoxic T Lymphocyte Response to Capsid
Since first described in humans, there still remains no suitable animal
model to predict the immunotoxicities observed in patients.5,38 In
murine models, capsid CD8+ T cells can be induced following IM
and i.v. injection of an AAV vector.65–68 One hypothesis proposed
that capsids dependent on heparin for cell entry are acquired by DCs
and presented to capsid T cells.69 Despite data supporting this hypoth-
esis in both mice and NHPs,69 this was not observed in humans.70 A
surrogate capsid epitope, the immunodominant H-2Kb ovalbumin
epitope SIINFEKL, was introduced into the AAV capsid to better track
responses with epitope-specific reagents. Studies in C57BL/6 mice
showed that AAV2-SIINFEKL and AAV8-SIINFEKL vectors activated
capsid CD8+ T cells and could induce proliferation of adoptively trans-
ferred dye labeled OT-I CD8+ T cells, CD8+ T cells from mice trans-
genic for the SIINFEKL MHC-I restricted T cell receptor (TCR).71–73
However, despite showing that capsid CD8+ T cells could kill
peptide-pulsed target cells in vivo, these cells failed to eliminate
AAV-SIINFEKL transduced hepatocytes.65 Further, studies in mice
focusing on the generation of capsid memory CD8+ T cells and their
subsequent activation following AAV liver gene delivery also failed
to induce clearance of AAV transduced hepatocytes.74
IM injection of an AAV2 or AAV6 vector in wild-type outbred dogs
resulted in a robust T cell immune response to capsid that was inde-
pendent of transgene and promoter.75 A more recent study found
evidence of a capsid CD8+ T cell response in a hemophilia A dog
retreated with a second dose of an AAV8-cF8 vector with mild
elevation in ALT.52 However, it is unclear if the interferon-gamma
(IFN-g)-secreting capsid CD8+ T cells detected at day 17 were related
to the loss in transgene as inhibitory anti FVIII antibodies were
detected at day 59 post vector, likely explaining the loss in coagulation
activity.52 Long-term analysis of i.v.-injected NHPs heterozygous for
LDLR/+ with an AAV8-hLDLR vector showed a wide range of
responses including capsid CD8+ T cells in peripheral blood, liver,
spleen, and bone marrow.76
A new mouse model was developed based on the in vivo and in vitro
expansion of capsid reactiveCD8+T cells using theH2-Ld native immu-
nodominant capsid epitope sharedbybothAAV2andAAV8capsids, as
well as humanHLA-B*0702.77Adoptive transfer of these expanded and
activated capsid CD8+ T cells into AAV transduced immune-deficient
recipient mice demonstrated specific hepatocyte killing with transient
transaminitis.77 In vivo administered PI or engineered capsids with
reduced capsid epitope presentation suppressed capsid-specific CD8+
T cell elimination of hepatocytes.77 Follow-up studies demonstrated
that an immune-deficient recipient was not necessary,78 possibly allow-
ing for the generation and testing of capsidCD8+T cellswithin the same
animal. However, mouse-based models are presently not able to
evaluate human hepatotropic capsids79 and humanized mice with
human immune systems and livers require further development.38,80
Cross-Presentation of AAV Capsid
Classic MHC-I presentation by APCs is restricted to endogenously
synthesized and proteasomal degraded proteins. However, certainar Therapy: Methods & Clinical Development Vol. 17 June 2020 201
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MHC-I presentation of epitopes derived from exogenous proteins,
such as viruses or pathogens, which are normally relegated to
MHC-II presentation. Cross-presentation of AAV capsid and pri-
mary activation of capsid-specific CD8+ T cells has been discussed
as an alternative hypothesis to the activation of memory capsid
CD8+ T cells and immunotoxicity.38 Several murine studies support
that cross-presentation of AAV vectors plays a role in activating
cellular immunity against the AAV capsid.6,65,68 Capsid CD8+
T cell responses were shown to be significantly diminished in
TLR9/, MyD88/, and IFNR/ mice, suggesting an important
role for pDCs and type I IFN in activating cell-mediated immunity
to AAV vectors.11 Mechanistic studies in mice revealed a co-operative
role between plasmacytoid pDCs and cDCs for inducing a primary
CD8+ T cell response directed against the capsid.65 These studies
demonstrated that cross-presentation of capsid-derived epitopes to
CD8+ T cells was dependent on TLR9 sensing of the AAV vector
genome by pDCs and subsequent licensing of cDCs mediated by
release of type I IFN from pDCs.65
Animal Model to Evaluate the Effectiveness of Prednisone on
Capsid CD8+ T Cell Responses
Despite extensive use in recent AAV clinical trials, there have been
limited reports of pre-clinical studies evaluating the effectiveness of
prednisone in dampening immune responses to AAV capsid. Prophy-
lactic oral prednisone was evaluated in rhesus macaques receiving an
IM injection of an AAVrh74-MCK-GALGT2 vector.81 Analysis of
injected skeletal muscle revealed a reduction in infiltrating mononu-
clear cellular infiltrates, which consisted primarily of CD8+ and
FoxP3+ regulatory T cells,81 similar to what has been reported in
human clinical trials investigating IM AAV gene delivery.82,83
Infiltrating CD8+ T cells displayed an exhausted phenotype with up-
regulation of the death receptor PD1 as similarly reported in a study
of CD8+ T cell responses to wild-type AAV8 natural infection in
rhesus macaques.31 There was a trend toward reduced anti-AAVrh74
antibodies and IFN-g ELISpot counts against capsid and GALGT2
epitopes in prednisone treated macaques however, due to the small
group size did not reach significance. Elevated PDL2 expression on
AAV transduced skeletal myofibers along with infiltrating regulatory
T cells was suggested as the reason for persistent transgene expression
in the presence of infiltrating CD8+ T cells.
Transgene Product Immune Responses
Animal studies have identified multiple factors influencing transgene
product immunity including AAV capsid and genome,16,73,77,84,85
delivery route,86,87 underlying mutation,86 use of tissue-restricted
promoters,88 genetic background,88 and disease-related inflamma-
tion.89 Two examples from human clinical trials highlight this
complexity. Adaptive CD8+ T cell immune response against trans-
gene product was identified in several Duchenne muscular dystrophy
(DMD) patients treated with IM delivery of an AAV1 vector express-
ing the mini-dystrophin protein.90 However, this response was not
uniform among patients within the same dose cohort. In another clin-
ical study, AAV1-hA1AT muscle gene transfer identified a cellular202 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2immune response against the transgene product, in a patient with a
homozygous polymorphism in AAT combined with a rare HLA-C
allele.91 While not exhaustive, these examples show that the integra-
tion of many factors is involved in the acceptance or rejection of a
therapeutic transgene product by the immune system
Humoral and Cell-Mediated Transgene Product Immunity
Muscle Gene Delivery
IM gene delivery of AAV vectors has been studied for both correction
of muscle related diseases such as muscular dystrophies and Pompe
disease and as a minimally invasive tissue for AAV transduction to
produce FIX in hemophilia B and alpha-1 antitrypsin (AAT).
However, IM delivery of AAV vectors often results in potent humoral
and cell-mediated immune responses directed against the transgene
product.86,92,93 Early studies in mice showed that IM injection of
AAV vectors induced functionally impaired CD8+ T cells.94,95 In
wild-type C57BL/6 mice, the risk of a FIX antibody response was
dependent on the dose and route of vector administration with IM
delivery shown to be substantially more immunogenic compared to
intraportal vector administration.59 In hemophilia B dogs, the capsid
serotype and transgene product expression levels were shown to
impact the risk for FIX antibodies as IM delivery of an AAV2 vector
was tolerated,96 whereas treatment with an AAV1 vector resulted in
the formation of anti-FIX antibodies.92
Studies in animals have also revealed that the genetic mutation plays
an important factor in determining transgene product immunity.97
Several lines of hemophilia B mice transgenic for different human
F9 mutations were generated98 and backcrossed onto the C3H/HeJ
background. Animals transgenic for a missense mutation of hF9
expressing a non-functional FIX protein developed a weaker FIX im-
mune response compared to null and early stopmutants following IM
injection of an AAV2-F9 vector.86 Similar outcomes were observed in
hemophilia B dogs with either a missense or null mutation for canine
F9.99 However, IM delivery of an AAV-cF9 vector into hemophilia B
dogs with a missense mutation showed a dose per injection site risk
for a T cell-dependent anti-cFIX immunoglobulin G (IgG) response,
suggesting that local inflammation may contribute to transgene im-
munity.100 This is reflected in canine DMD models where disease-
associated muscle inflammation requires the use of immune suppres-
sion for sustained expression of canine micro-dsytrophin.101
Transgene product acquired from transduced muscle cells is cross-
presented on APCs102 where TLR9 sensing of the AAV genome,
MyD88, and IFNR were shown to be critical for productive transgene
product-specific adaptive immune responses following IM AAV
delivery.11,19,84 An immunogenic hybrid capsid, rh32.33, was shown
to provide modulatory signaling in activating transgene product im-
munity;103 however, this activity was dependent on TLR9 activation,
as depletion of TLR9 stimulatory CpG motifs in the AAV genome
ablated transgene product immunity.84 Further, TLR9 activation
was shown to enhance transgene product immunity following
AAV1-hF9 IM delivery in C57BL/6 mice, which are normally tolerant
to IM AAV1-hF9 gene transfer.17 scAAV vectors, independent of020
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mediated immune responses in mice.85 However, a F9 missense mu-
tation superseded the enhanced TLR9 activation of the scAAV1-F9
vector, resulting in ablation of FIX CD8+ T cell immunity.104
Several approaches have been tested in mice to limit transgene prod-
uct immunity following IM AAV gene delivery including vector
genome engineering to remove TLR9 stimulatory CpGs,84 tissue-spe-
cific promoters and hematopoietic lineage microRNA (miRNA) tar-
gets 142-3p,105 transient immune modulation,40,106 and dual expres-
sion of transgene in liver and muscle.107–110 Studies in large animal
models have shown that the delivery route, direct IM injection versus
regional vascular delivery, also impacts transgene immunity.111 A
recently published study reports 5-year inducible expression of the
immunogenic doxycycline Tet-On system in NHPs following local
regional delivery of an AAV vector with no detectable transgene
product immune responses.112
Ocular Gene Delivery
Early preclinical studies for ocular gene therapy did not predict the
inflammation observed in several patients receiving subretinal injection
of an AAV2 vector.113 However, lack of an immune response for ocular
gene transfer in pre-clinical studies was expected, since the ocular
compartment is considered to be immune privileged. One potential
explanation is that the capsid serotype and delivery routes investigated
may have contributed to masking this response. For example, RPE65-
deficient dogs treated with subretinal injection of anAAV4-RPE65 vec-
tor did not report any incidence of ocular inflammation.114 An AAV2-
RPE65 subretinal injection into RPE65 null dogs demonstrated mild
and transient ocular inflammation when using a highly purified vector
prep,115 whereas other studies in dogs reported much more severe
inflammation.116,117 More recent studies in NHPs show that subretinal
delivery of an AAV8 vector can induce a transient local innate and
adaptive immune response including recruitment of CD8+ T cells
and CD20+ B cells into the retina.21
Liver Gene Delivery, Transgene Product Immunity, and
Tolerance
Transgene product tolerance with AAV-targeted liver gene therapy is
dependent on the induction and persistence of regulatory T cells
(Tregs).88,118–121 Supporting studies in a large animal model demon-
strated that treatment of NHPs with daclizumab (anti-CD25 anti-
body), sirolimus, and mycophenolate mofetil broke tolerance against
FIX protein following AAV2-F9 gene transfer due to depletion of
Tregs.122 Several studies inmice have shown that AAV liver transgene
product tolerance is also dependent on protein expression
levels.87,88,123,124 The vector dose dependency of transgene product
tolerance was further shown using an AAV8-EF1a-ova vector in
C57BL/6 mice.124 Mice receiving an intermediate vector dose
expanded ova-specific CD8+ T cells with an initial exhausted pheno-
type resulting in persistent transgene expression. However, over time,
the ova-specific CD8+ T cells became activated and eliminated ova-
expressing hepatocytes,124 whereas mice receiving the highest vector
dose maintained stable ova expression with an undetectable ova-spe-Moleculcific CD8+ T cell response.124 Although this study expressed ova from
an ubiquitous promoter, tolerance induction was shown to be more
effective when transgene product expression is restricted to hepato-
cytes by both promoter selection88 and hepatotropic capsids.87
Most studies evaluating liver transgene product tolerance focused on
secreted proteins, which could easily be measured in blood. Thus, it
was unclear whether a non-secreted protein would promote immune
tolerance. Liver transduction by an AAV2-LacZ vector prior to an
Ad-LacZ vector resulted in sustained expression and suppression of
transgene-specific CD8+ T cell activation that was seen in Ad-LacZ
only treated controls.107 Expression of a membrane-bound ova pro-
tein in hepatocytes was shown to prevent airway-induced allergy
mediated by Treg induction.125 And finally, administration of an
AAV8-MOG vector was shown to prevent and reverse disease in
experimental autoimmune encephalomyelitis (EAE) mice, a model
for multiple sclerosis.126 Overall, the data show that tolerance is not
dependent on a secreted transgene product.
Mechanistic studies in mice have identified an important role for
transforming growth factor b (TGF-b) and IL-10,127 glucocorti-
coid-induced TNFR-related protein (GITR) and GITRL interac-
tion,128 anergy, and deletion by Fas-FasL induced apoptosis.88,119,129
Studies in immune-deficient mice transgenic for the ova CD4+ TCR
investigated where transgene presentation and conversion of CD4+
T helper cells into Treg occurred following AAV8 liver gene transfer
of a secreted or non-secreted ova antigen.130 Mice expressing the non-
secreted ova presented ova to CD4+ T cells in the liver and liver drain-
ing lymph nodes and induced Treg were rapidly disseminated in the
peripheral circulation,130 whereas mice expressing a secreted ova had
both extra-thymic and thymic Treg induction. Bothmacrophages and
to a lesser extent cDCs were identified as critical APCs for CD4+ T cell
activation and peripheral Treg induction.130
AAV transgene product tolerance in the liver has allowed for trans-
duction and supplemental gene expression using a more immuno-
genic vector108 or tissue.109,110,131 Further, several groups have
demonstrated that established anti-drug antibodies to the transgene
product could be eliminated by AAV liver gene transfer in murine123
and canine132,133 hemophilia models, as well as in a murine Pompe
disease model.134 Additionally, AAV liver transgene product toler-
ance was successful in preventing and reversing paralysis in the
EAE mouse model.126 There are several studies in large animal
models supporting AAV-mediated transgene product tolerance.
Liver-directed gene delivery of an AAV2 vector in hemophilia B
dogs with a null mutation, which are prone to generate anti-FIX an-
tibodies from IM delivery, provided over 10 years of FIX expression
without any evidence of transgene product antibodies.135,136 Another
study in NHPs demonstrated that transgene tolerance could be
induced with an AAV8-alpha-galactosidase A vector despite reduced
transcription and expression of the transgene as compared to mice.137
It should be noted that AAV transgene product liver tolerance
may not always be effective. Expression of human proteins such asar Therapy: Methods & Clinical Development Vol. 17 June 2020 203
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response and may require immune suppression to restore therapeutic
expression.53,54,138 A recent study evaluating a clinical AAV8 vector
expressing human UGUT1A1 in NHPs reported a mainly transgene
product T cell response and found that peripheral transgene product
T cell responses did not always correlate with the local T cell response
in the liver.139 Insulin gene therapy with an AAV8 vector in non-
obese diabetic (NOD) mice found that immune suppression was
needed to maintain insulin expression, suggesting that liver tolerance
alone was not sufficient to overcome established autoimmunity.140
However, it should be noted that NOD mice have a genetic predispo-
sition for autoimmunity and that the target level of insulin required
for therapeutic benefit may be below the threshold need for tolerance
induction.
Conclusions
Despite a growing level of insight into AAV vector immunity from
animal studies, it is unclear whether a single model will be able to
completely predict human responses. Mouse models have provided
data on feasibility of disease correction, potential risks of transgene
product and vector immunity in the context of disease model, AAV
serotype, target organ, and delivery route. Recent studies have also
begun to identify critical mechanisms of AAV vector sensing and acti-
vation of adaptive immune responses and tested vector modifications
and targeted therapies to blunt these responses. However, the genetic
uniformity of inbred strains and absence of natural infection with
AAVs make it difficult to fully extrapolate outcomes in human
studies. Studies in larger animal systems including dogs and NHPs
have also provided more valuable insights into vector-mediated safety
and to some extent efficacy. The scarcity of genetic NHP disease
models and high risk of transgene immunity when human proteins
are expressed in dogs and NHPs make it difficult to take advantage
of their longer lifespans to evaluate clinical vector preparations for
long-term transgene product expression, efficacy, and vector and
transgene product immunity.
Ultimately, humans will likely be the best animal model to study AAV
immunity with experience gained from the use of approved AAV bi-
ologics and clinical trials. However, several important questions still
remained unanswered. Can testing of peripheral blood mononuclear
cells predict CD8+ T cell responses against AAV capsid and rejection
of therapy and how can we better screen patients? Is the immunotox-
icity in humans a de novo immune response or a recall response? Are
there toxicities unrelated to vector immunity? What is the best im-
mune suppression protocol, agent, and treatment window to prevent
capsid related immunotoxicity? What is the optimal vector dose for
each capsid serotype to avoid immunity while providing therapeutic
transgene expression? Continued research into AAV vector immu-
nity and associated toxicities and the generation of new and improved
animal models may help to address these questions.
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